1. Academic Validation
  2. Computational Design of Lysine Targeting Covalent Binders Using Rosetta

Computational Design of Lysine Targeting Covalent Binders Using Rosetta

  • J Chem Inf Model. 2025 Jun 9;65(11):5612-5622. doi: 10.1021/acs.jcim.5c00212.
Barr Tivon 1 Jan Wiese 2 Matthias P Müller 2 Ronen Gabizon 1 Daniel Rauh 2 Nir London 1
Affiliations

Affiliations

  • 1 Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot 7610001, Israel.
  • 2 Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, Dortmund 44227, Germany.
Abstract

Chemical probes that form a covalent bond with their target protein have been established as a powerful tool for investigating proteins and modulating their activity, but until recently were mostly targeting cysteine residues. Covalent Binders that target lysine residues are increasingly reported. Covalent binding to lysine involves challenges such as the increased pKa of the side chain and its considerable flexibility. Here, we describe two computational methods to derivatize lysine-binding covalent small-molecules based on known noncovalent Binders, approaching the design problem from two opposite directions. In a "ligand-side" approach, we scan different ligand positions to install an electrophile and DOCK these derivatized ligands into the target protein. In a "protein-side" approach, we install an electrophile on the target lysine and model its conformational space to find suitable installation vectors on the ligand. We applied both of these protocols retrospectively to a data set of electrophilic ligands and to a data set of vitamin B6 covalently bound to a receptor lysine residue. Our ligand-side protocol successfully identified the known covalent binder in 80% and 86% of cases, while the protein-side protocol achieved identification rates of 56% and 82%, respectively. We prospectively validated these protocols by designing and testing a new lysine-targeting MKK7 inhibitor. Mass-spectrometry and crystallography validated the covalent binding to the target lysine. Applying these protocols to a data set of known kinase inhibitors identified high-confidence covalent candidates for more than 200 human kinases, demonstrating the potential impact of our protocols.

Figures
Products